More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/IBMX [28822-58-4]
Chemical Structure
Chemical Structure
Chemical Structure

IBMX [28822-58-4]

Research Use Only
AG-CR1-3512
AdipoGen Life Sciences
CAS Number28822-58-4
DownloadDatasheet
DownloadMSDS
Product group Chemicals
Estimated Purity>99%
Molecular Weight222.3
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    IBMX [28822-58-4]
  • Delivery Days Customer
    10
  • CAS Number
    28822-58-4
  • Certification
    Research Use Only
  • Estimated Purity
    >99%
  • Hazard Information
    Non-hazardous,Warning
  • Molecular Formula
    C10H14N4O2
  • Molecular Weight
    222.3
  • Scientific Description
    Cell permeable, competitive, non-specific cAMP and cGMP phosphodiesterase inhibitor [1, 5, 6, 11]. Increases cAMP levels that activate PKA, leading to decreased proliferation, increased differentiation and induction of apoptosis [9]. Enhances differentiation of 3T3-L1 cells [3]. Non-selective adenosine receptor antagonist [4]. Inhibits Ca2+ ion channels [7, 8]. Activates TNF-alpha [10]. Adipogenic [10]. Activates leukotriene synthesis [12]. Reduces inflammation and innate immunity [12]. - Chemical. CAS: 28822-58-4. Formula: C10H14N4O2. MW: 222.3. Cell permeable, competitive, non-specific cAMP and cGMP phosphodiesterase inhibitor. Increases cAMP levels that activate PKA, leading to decreased proliferation, increased differentiation and induction of apoptosis. Enhances differentiation of 3T3-L1 cells. Non-selective adenosine receptor antagonist. Inhibits Ca2+ ion channels. Activates TNF-alpha. Adipogenic. Activates leukotriene synthesis. Reduces inflammation and innate immunity.
  • SMILES
    CC(C)CN1C2=C(NC=N2)C(=O)N(C)C1=O
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200

References

  • Effects of xanthine derivatives on lipolysis and on adenosine 3',5'- monophosphate phosphodiesterase activity: J.A. Beavo, et al.; Mol. Pharmacol. 6, 597 (1970)
  • Inhibition of growth of primary and metastatic Lewis lung carcinoma cells by the phosphodiesterase inhibitor isobutylmethylxanthine: P. Janik, et al.; Cancer Res. 40, 1950 (1980)
  • A role for soluble cAMP phosphodiesterases in differentiation of 3T3-L1adipocytes: M.L. Elks & V.C. Manganiello; J. Cell Physiol. 124, 191 (1985)
  • Adenosine receptors: development of selective agonists and antagonists: J.W. Daly, et al.; Prog. Clin. Biol. Res. 230, 41 (1987)
  • Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors: J.A. Beavo & D.H. Reifsnyder; TIPS 11, 150 (1990)
  • Isobutylmethylxanthine and other classical cyclic nucleotide phosphodiesterase inhibitors affect cAMP-dependent protein kinase activity: C. Tomes, et al.; Cell Signal. 5, 615 (1993)
  • IBMX induces calcium release from intracellular stores in rat sensory neurones: Y. Usachev & A. Verkhratsky; Cell Calcium 17, 197 (1995)
  • Inhibition of recombinant human cardiac L-type Ca2+ channel alpha1C subunits by 3-isobutyl-1-methylxanthine: I.M. Fearon, et al.; Eur. J. Pharmacol. 342, 353 (1998)
  • Up-regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas: T.C. Chen, et al.; Lab. Invest. 78, 165 (1998)
  • The phosphodiesterase inhibitor IBMX suppresses TNF-alpha expression in human adipocyte precursor cells: a possible explanation for its adipogenic effect: F. Hube, et al.; Horm. Metab. Res. 31, 359 (1999)